A 52-week, randomized, double-blind, double-dummy, parallel-group, multicenter, non-inferiority study to investigate the efficacy and safety of depemokimab compared to mepolizumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA). English) relapsed or refractory that receive the usual treatment